These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2002475)

  • 1. Specific bradycardic agents. 2. Heteroaromatic modifications in the side chain of specific bradycardic benzazepinones: chemistry, pharmacology, and structure-activity relationships.
    Bomhard A; Reiffen M; Heider J; Psiorz M; Lillie C
    J Med Chem; 1991 Mar; 34(3):942-7. PubMed ID: 2002475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties.
    Reiffen M; Eberlein W; Müller P; Psiorz M; Noll K; Heider J; Lillie C; Kobinger W; Luger P
    J Med Chem; 1990 May; 33(5):1496-504. PubMed ID: 2261014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".
    Kobinger W; Lillie C
    Eur J Pharmacol; 1984 Sep; 104(1-2):9-18. PubMed ID: 6499920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific bradycardic agents, a new therapeutic modality for anesthesiology: hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs.
    Riley DC; Gross GJ; Kampine JP; Warltier DC
    Anesthesiology; 1987 Nov; 67(5):707-16. PubMed ID: 3674471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of N-acyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel specific bradycardic agents.
    Kubota H; Watanabe T; Kakefuda A; Masuda N; Wada K; Ishii N; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Mar; 12(5):871-82. PubMed ID: 14980599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zatebradine on contractility, relaxation and coronary blood flow.
    Breall JA; Watanabe J; Grossman W
    J Am Coll Cardiol; 1993 Feb; 21(2):471-7. PubMed ID: 8426013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological activity of some 1,3-dihydro-2H-3-benzazepin-2-ones with a piperazine moiety as bradycardic agents.
    Liang HY; Zhang DQ; Yue Y; Shi Z; Zhao SY
    Arch Pharm (Weinheim); 2010 Feb; 343(2):114-9. PubMed ID: 20108265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site.
    Stähle H; Daniel H; Kobinger W; Lillie C; Pichler L
    J Med Chem; 1980 Nov; 23(11):1217-22. PubMed ID: 7452671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs.
    Krumpl G; Winkler M; Schneider W; Raberger G
    Br J Pharmacol; 1988 May; 94(1):55-64. PubMed ID: 3401644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.
    Lillie C; Kobinger W
    J Cardiovasc Pharmacol; 1986; 8(4):791-7. PubMed ID: 2427820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional redistribution of myocardial perfusion by UL-FS 49, a selective bradycardic agent.
    O'Brien P; Drage D; Saeian K; Brooks HL; Warltier DC
    Am Heart J; 1992 Mar; 123(3):566-74. PubMed ID: 1539507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats.
    Gardiner SM; Kemp PA; March JE; Bennett T
    Br J Pharmacol; 1995 Jun; 115(4):579-86. PubMed ID: 7582475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (+/-)-2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinolines as a new class of specific bradycardic agents.
    Kubota H; Kakefuda A; Watanabe T; Taguchi Y; Ishii N; Masuda N; Sakamoto S; Tsukamoto Si
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2155-8. PubMed ID: 12798325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of a potassium channel blocking drug, UK-68,798, and a specific bradycardic agent, UL-FS 49, on exercise-induced ischemia in the dog: significance of diastolic time on ischemic cardiac function.
    Gout B; Jean J; Bril A
    J Pharmacol Exp Ther; 1992 Sep; 262(3):987-94. PubMed ID: 1527735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective and specific reduction in the heart rate: a promising direction in the creation of new cardiovascular drugs].
    Chichkanov GG; Tsorin IB
    Eksp Klin Farmakol; 2007; 70(4):66-71. PubMed ID: 18078045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypotensive and bradycardic activities of clonidine and related imidazolidines; structure-activity relationship.
    Timmermans PB; Van Zwieten PA
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):237-50. PubMed ID: 921414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New cardiovascular acting 2-aryl-2-imidazolinyl-acetic acids. Synthesis and pharmacologic effects].
    Beyerle R; Bohn H; Schönafinger K; Martorana PA; Bender H
    Arzneimittelforschung; 1985; 35(1):93-102. PubMed ID: 2859025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bradycardic agent, UL-FS 49, increases atrial force and decreases ventricular force in isolated, perfused heart preparations of dogs.
    Furukawa Y; Takayama S; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1993 May; 265(2):801-6. PubMed ID: 8496825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of 1-oxo-2-(3-piperidyl)-1,2,3,4- tetrahydroisoquinolines and related analogues as a new class of specific bradycardic agents possessing I(f) channel inhibitory activity.
    Kubota H; Kakefuda A; Watanabe T; Ishii N; Wada K; Masuda N; Sakamoto S; Tsukamoto S
    J Med Chem; 2003 Oct; 46(22):4728-40. PubMed ID: 14561092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers.
    Ragueneau I; Laveille C; Jochemsen R; Resplandy G; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1998 Aug; 64(2):192-203. PubMed ID: 9728900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.